Brief: Rxsight Q2 Revenue USD 33.6 Million Vs. IBES Estimate USD 39.8 Million

RxSight

08/07/2025 21:05

Overview

RxSight's preliminary Q2 2025 revenue expected to be down 4% yr/yr, missing analyst expectations, per LSEG data

Company revises 2025 revenue guidance downward, gross margin guidance upward

Sale of Light Delivery Devices decreased 45% compared to Q1 2025

Outlook

RxSight revises 2025 revenue guidance to $120 mln-$130 mln, down from $160 mln-$175 mln.

Company increases 2025 gross margin guidance to 72%-74%, up from 71%-73%.

RxSight sees 2025 operating expense guidance between $145 mln-$155 mln.

Result Drivers

REVENUE DECLINE - Q2 2025 revenue expected to fall 4% year-over-year and 11% from Q1 2025, missing analyst expectations, on decreased sales of Light Delivery Devices

LDD SALES DROP - Sales of Light Delivery Devices decreased 45% compared to Q1 2025 and 49% compared to Q2 2024

LAL SALES GROWTH - Despite overall revenue decline, Light Adjustable Lenses sales increased 13% compared to Q2 2024

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Miss
$33.60 mln
$39.80 mln (10 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 3 "hold" and 2 "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Rxsight Inc is $21.00, about 40.8% above its July 7 closing price of $12.43

Press Release: ID:nGNX2LHj70

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)